These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 15507937)

  • 1. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
    Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR; Gründker C; Bongertz T; Nagy A; Schally AV; Emons G
    Breast Cancer Res Treat; 2004 Oct; 87(3):255-64. PubMed ID: 15528968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
    Günthert AR; Gründker C; Böttcher B; Emons G
    Anticancer Res; 2004; 24(3a):1727-32. PubMed ID: 15274347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
    Emons G; Sindermann H; Engel J; Schally AV; Gründker C
    Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
    Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
    Westphalen S; Kotulla G; Kaiser F; Krauss W; Werning G; Elsasser HP; Nagy A; Schulz KD; Grundker C; Schally AV; Emons G
    Int J Oncol; 2000 Nov; 17(5):1063-9. PubMed ID: 11029513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
    Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
    Nagy A; Schally AV
    Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells.
    Günthert AR; Gründker C; Hollmann K; Emons G
    Biochem Biophys Res Commun; 2002 May; 294(1):11-5. PubMed ID: 12054733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin-doxorubicin sensitivity.
    Gebauer G; Mueller N; Fehm T; Berkholz A; Beck EP; Jaeger W; Licht P
    Am J Obstet Gynecol; 2004 Jun; 190(6):1621-8; discussion 1628. PubMed ID: 15284756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
    Gründker C; Völker P; Emons G
    Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
    Gründker C; Völker P; Schulz KD; Emons G
    Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma.
    Irmer G; Bürger C; Müller R; Ortmann O; Peter U; Kakar SS; Neill JD; Schulz KD; Emons G
    Cancer Res; 1995 Feb; 55(4):817-22. PubMed ID: 7850795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
    Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
    Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells.
    Gründker C; Schulz K; Günthert AR; Emons G
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3815-20. PubMed ID: 11061544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
    Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G
    Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.